Literature DB >> 10073321

Recent advances in our understanding of the use of theophylline in the treatment of asthma.

C P Page1.   

Abstract

The use of theophylline for the treatment of asthma for 45 of the past 50 years has been for its ability to dilate bronchi. The problem has been that at the most effective bronchodilating dose, toxicity was too close for comfort. In the past 5 years, there has been resurgence in theophylline use at lower doses because of some well-documented anti-inflammatory and steroid sparing effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073321

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

Review 1.  Asthma--the changing face of drug therapy.

Authors:  J Legg; J Warner
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

2.  Enhancement of the anti-inflammatory and anti-arthritic effects of theophylline by a low dose of a nitric oxide donor or non-specific nitric oxide synthase inhibitor.

Authors:  Adel Gomaa; Mohsen Elshenawy; Noha Afifi; Eman Mohammed; Romany Thabit
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.

Authors:  Alexandre Trifilieff; Thomas H Keller; Neil J Press; Trevor Howe; Peter Gedeck; David Beer; Christoph Walker
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

4.  Synthesis and in vitro Efficacy Studies of Silver Carbene Complexes on Biosafety Level 3 Bacteria.

Authors:  Matthew J Panzner; Arpaporn Deeraksa; Alyssa Smith; Brian D Wright; Khadijah M Hindi; Aysegul Kascatan-Nebioglu; Alfredo G Torres; Barbara M Judy; Christine E Hovis; Julia K Hilliard; Rebekah J Mallett; Emily Cope; D Mark Estes; Carolyn L Cannon; Jeff G Leid; Wiley J Youngs
Journal:  Eur J Inorg Chem       Date:  2009-05-01       Impact factor: 2.524

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.